Pharmaron Beijing Co., Ltd. Class H (3759) Stock Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3759 Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Pharmaron

Beijing Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3759 Stock 12 Month Forecast

Average Price Target

HK$30.69

▲(27.13% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Pharmaron Beijing Co., Ltd. Class H in the last 3 months. The average price target is HK$30.69 with a high forecast of HK$33.70 and a low forecast of HK$28.13. The average price target represents a 27.13% change from the last price of HK$24.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"HK$7","34":"HK$34","13.75":"HK$13.75","20.5":"HK$20.5","27.25":"HK$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.702015744,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$33.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.688014336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$30.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.130679808,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$28.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.75,20.5,27.25,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Sep<br/>2024","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.844770441846155,29.24954088369231,29.654311325538462,30.059081767384615,30.46385220923077,30.868622651076926,31.27339309292308,31.678163534769233,32.08293397661539,32.48770441846154,32.89247486030769,33.29724530215385,{"y":33.702015744,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.61292417969231,28.785848359384616,28.958772539076925,29.13169671876923,29.30462089846154,29.477545078153845,29.650469257846154,29.82339343753846,29.99631761723077,30.169241796923075,30.342165976615384,30.515090156307693,{"y":30.688014336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.416206139076923,28.39241227815385,28.36861841723077,28.344824556307692,28.321030695384618,28.29723683446154,28.27344297353846,28.249649112615383,28.22585525169231,28.20206139076923,28.178267529846153,28.154473668923078,{"y":28.130679808,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.786,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.786,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.786,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.786,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.786,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.786,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.447,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.803,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.178,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.678,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$33.70

Average Price TargetHK$30.69

Lowest Price TargetHK$28.13

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$24.7→HK$28.8

Buy

19.30%

Upside

Reiterated

10/30/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$26.6→HK$30

Buy

24.28%

Upside

Reiterated

10/30/25

Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Goldman Sachs

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$28.54→HK$33.69

Buy

39.56%

Upside

Reiterated

10/29/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$31→HK$32.9

Buy

36.29%

Upside

Reiterated

10/28/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$23.3→HK$26.6

Buy

10.19%

Upside

Reiterated

10/17/25

Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from Goldman Sachs

Linda Shu

HSBC

HK$28.1

Buy

16.40%

Upside

Reiterated

10/15/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$31

Buy

28.42%

Upside

Reiterated

09/15/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$20.5→HK$23.3

Buy

-3.48%

Downside

Reiterated

08/25/25

Goldman Sachs Keeps Their Buy Rating on Pharmaron Beijing Co., Ltd. Class H (17Q1)

Ruili Bian

Citi

HK$33→HK$39

Buy

61.56%

Upside

Reiterated

08/25/25

Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from CitiCiti analyst Zoe Bian raised the price target on Pharmaron Beijing Co Ltd (3759:HK) to HK$39.00 (from HK$33.00) while maintaining a Buy rating.

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$25

Buy

3.56%

Upside

Reiterated

08/25/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$24.7

Buy

2.32%

Upside

Reiterated

08/22/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$28.54

Buy

18.23%

Upside

Reiterated

08/22/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$26

Buy

7.71%

Upside

Reiterated

08/22/25

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$23.3

Buy

-3.48%

Downside

Reiterated

08/22/25

Unknown Analyst

Nomura

Not Ranked

Nomura

HK$26.63

Buy

10.31%

Upside

Reiterated

08/21/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$24.7→HK$28.8

Buy

19.30%

Upside

Reiterated

10/30/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$26.6→HK$30

Buy

24.28%

Upside

Reiterated

10/30/25

Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Goldman Sachs

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$28.54→HK$33.69

Buy

39.56%

Upside

Reiterated

10/29/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$31→HK$32.9

Buy

36.29%

Upside

Reiterated

10/28/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$23.3→HK$26.6

Buy

10.19%

Upside

Reiterated

10/17/25

Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from Goldman Sachs

Linda Shu

HSBC

HK$28.1

Buy

16.40%

Upside

Reiterated

10/15/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$31

Buy

28.42%

Upside

Reiterated

09/15/25

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

HK$20.5→HK$23.3

Buy

-3.48%

Downside

Reiterated

08/25/25

Goldman Sachs Keeps Their Buy Rating on Pharmaron Beijing Co., Ltd. Class H (17Q1)

Ruili Bian

Citi

HK$33→HK$39

Buy

61.56%

Upside

Reiterated

08/25/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$25

Buy

3.56%

Upside

Reiterated

08/25/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$24.7

Buy

2.32%

Upside

Reiterated

08/22/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$28.54

Buy

18.23%

Upside

Reiterated

08/22/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$26

Buy

7.71%

Upside

Reiterated

08/22/25

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$23.3

Buy

-3.48%

Downside

Reiterated

08/22/25

Unknown Analyst

Nomura

Not Ranked

Nomura

HK$26.63

Buy

10.31%

Upside

Reiterated

08/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharmaron Beijing Co., Ltd. Class H

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+20.60%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +20.60% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+0.80%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +0.80% per trade.

1 Year

Linda ShuHSBC

Success Rate

1/3 ratings generated profit

Average Return

-9.13%

reiterated a buy rating 2 months ago

Copying Linda Shu's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.13% per trade.

2 Years

xxx

Success Rate

1/3 ratings generated profit

Average Return

-9.13%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -9.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3759 Analyst Recommendation Trends

Rating

Mar 25

Apr 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3759 has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3759 average Analyst price target in the past 3 months is 30.69.

Each month's total comprises the sum of three months' worth of ratings.

3759 Financial Forecast

3759 Earnings Forecast

Next quarter’s earnings estimate for 3759 is HK$0.32 with a range of HK$0.28 to HK$0.36. The previous quarter’s EPS was HK$0.27. 3759 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.

3759 Sales Forecast

Next quarter’s sales forecast for 3759 is HK$4.36B with a range of HK$4.36B to HK$4.36B. The previous quarter’s sales results were HK$3.92B. 3759 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.

3759 Stock Forecast FAQ

What is HK:3759’s average 12-month price target, according to analysts?

Based on analyst ratings, Pharmaron Beijing Co., Ltd. Class H’s 12-month average price target is 30.69.

What is HK:3759’s upside potential, based on the analysts’ average price target?

Pharmaron Beijing Co., Ltd. Class H has 27.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pharmaron Beijing Co., Ltd. Class H a Buy, Sell or Hold?

Pharmaron Beijing Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Pharmaron Beijing Co., Ltd. Class H’s share price target?

The average share price target for Pharmaron Beijing Co., Ltd. Class H is 30.69. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$33.70 ,and the lowest forecast is HK$28.13. The average share price target represents 27.13% Increase from the current price of HK$24.14.

What do analysts say about Pharmaron Beijing Co., Ltd. Class H?

Pharmaron Beijing Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Pharmaron Beijing Co., Ltd. Class H?

To buy shares of HK:3759, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Pharmaron Beijing Co., Ltd. Class H (3759) Stock Forecast & Price Target

3759 Analyst Ratings

3759 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pharmaron Beijing Co., Ltd. Class H

3759 Analyst Recommendation Trends

3759 Financial Forecast

3759 Earnings Forecast

3759 Sales Forecast

3759 Stock Forecast FAQ

Detailed List of Analyst Forecasts